Related Experiment Videos
Time relationship between last dose of daunorubicin and congestive heart failure
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Improvements in Survival and Clinical Benefit With Gemcitabine as First-Line Therapy for Patients With Advanced Pancreas Cancer: A Randomized Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2023
Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas.
Annals of oncology : official journal of the European Society for Medical Oncology·2016
CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.
Annals of oncology : official journal of the European Society for Medical Oncology·2016
Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001).
Cancer chemotherapy and pharmacology·2014
Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies.
European journal of cancer (Oxford, England : 1990)·2012
Telomerase and telomere inhibitors in preclinical development.
Expert opinion on investigational drugs·2005
Cisplatin as a first-line treatment in T2 and T3 bladder carcinoma.
Cancer treatment reports·1987
IV melphalan in children.
Cancer treatment reports·1987
Interactions of methotrexate and cyclophosphamide with the pharmacokinetics of 5-fluorouracil in an animal model.
Cancer treatment reports·1987
Phase II trial of rDNA alfa 2b interferon in patients with malignant carcinoid tumor.
Cancer treatment reports·1987
Doxorubicin distribution in human breast cancer.
Cancer treatment reports·1987
Phase I study of echinomycin.
Cancer treatment reports·1987
Gradient Boosting Machine-Based Prognostic Model with SurvSHAP Analysis for Predicting Secondary Loss of Response to Infliximab Therapy in Crohn's Disease.
Drug design, development and therapy·2026
PCBP2 facilitates miR-93-5p-mediated repression of GDF11 in HCC cell lines.
Molecular therapy. Nucleic acids·2026
miRNA-34a-5p is a novel biomarker and modulator of the radioresponse in esophageal adenocarcinoma.
Molecular therapy. Nucleic acids·2026